DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
DANAHER CORP /DE/
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026
$224.43−4.61 (-2.01%)
Close on Oct 19, 2026
- Market cap
- $158.81B
- P/E (TTM)
- 39.9
- Dividend yield
- –
DANAHER CORP /DE/ revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $2.47B | $2.42B | – | – | $2.31B | $2.45B | – | – | – | – | – | – | 39.4% | +6.8% |
| Biotechnology | $1.92B | $1.80B | $2.03B | $1.80B | $1.85B | $1.61B | $1.87B | $1.65B | $1.71B | $1.52B | $1.76B | $1.66B | 30.6% | +3.8% |
| Life Sciences | $1.88B | $1.74B | – | – | $1.78B | $1.68B | – | – | – | – | – | – | 30.0% | +5.7% |
| Diagnostics | – | – | – | $2.46B | $2.31B | $2.45B | $2.64B | $2.36B | $2.26B | $2.53B | $2.72B | $2.25B | – | – |
| Environmental & Applied Solutions | – | – | – | – | – | – | – | – | – | – | – | $1.25B | – | – |
| Life Sciences | – | – | – | $1.79B | $1.78B | $1.68B | $2.03B | $1.78B | $1.77B | $1.75B | $1.93B | $1.71B | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology | $556.00M | $534.00M | $540.00M | $352.00M | $531.00M | $441.00M | $508.00M | $390.00M | $462.00M | $325.00M | $416.00M | $417.00M | +4.7% |
| Diagnostics | $416.00M | $674.00M | – | – | $554.00M | $718.00M | – | – | – | – | – | – | -24.9% |
| Life Sciences | $244.00M | $225.00M | – | – | -$239.00M | $201.00M | – | – | – | – | – | – | -202.1% |
| Diagnostics | – | – | – | $665.00M | $554.00M | $718.00M | $624.00M | $615.00M | $556.00M | $830.00M | $766.00M | $539.00M | – |
| Environmental & Applied Solutions | – | – | – | – | – | – | – | – | – | – | – | $286.00M | – |
| Life Sciences | – | – | – | $222.00M | -$239.00M | $201.00M | $376.00M | $35.00M | $233.00M | $235.00M | $235.00M | $313.00M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurring revenue | $5.20B | $5.03B | $5.32B | $5.02B | $4.97B | $4.82B | $5.11B | $4.78B | $4.69B | $4.80B | $4.99B | $4.44B | 83.0% | +4.6% |
| Nonrecurring revenue | $1.07B | $920.00M | $1.51B | $1.04B | $966.00M | $925.00M | $1.43B | $1.02B | $1.05B | $1.00B | $1.42B | $1.19B | 17.0% | +10.2% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $2.47B | $2.48B | $2.76B | $2.58B | $2.44B | $2.58B | $2.77B | $2.46B | $2.43B | $2.63B | $2.79B | $2.38B | 39.5% | +1.5% |
| High-growth markets | $1.96B | $1.62B | $2.03B | $1.76B | $1.70B | $1.54B | $1.91B | $1.72B | $1.70B | $1.54B | – | – | 31.3% | +15.4% |
| Western Europe | $1.54B | $1.57B | $1.69B | $1.40B | $1.51B | $1.34B | $1.49B | $1.32B | $1.32B | $1.32B | $1.42B | $1.20B | 24.6% | +2.2% |
| Other developed markets | $293.00M | $284.00M | $364.00M | $316.00M | $294.00M | $278.00M | $359.00M | $299.00M | $292.00M | $303.00M | – | – | 4.7% | -0.3% |
| High-growth markets | – | – | – | – | – | – | – | $1.72B | $1.70B | $1.54B | $1.85B | $1.75B | – | – |
| Other developed markets | – | – | – | – | – | – | – | $299.00M | $292.00M | $303.00M | $350.00M | $300.00M | – | – |
From the segment and revenue-disaggregation notes of Danaher's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.